Other drugs and convalescent plasma Source: Virtual Congress 2020 – Management Year: 2020
Convalescent plasma therapy in COVID-19 patients: Chinese and European perspectives Source: ERS webinar 2020: Convalescent plasma therapy in COVID-19 patients: Chinese and European perspectives Year: 2020
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma Source: Eur Respir J, 59 (2) 2101724; 10.1183/13993003.01724-2021 Year: 2022
Addition of convalescent plasma to systemic corticosteroids in early phase of COVID-19 Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021
Convalescent plasma for SARS-CoV-2 infection: win or learn Source: Eur Respir J, 59 (2) 2102076; 10.1183/13993003.02076-2021 Year: 2022
The efficacy of convalescent plasma therapy in severe COVID-19 patients: a systematic review Source: Virtual Congress 2021 – COVID19, acute respiratory failure and basic science Year: 2021
Anti-tuberculosis drug concentrations and treatment outcomes in patients with both tuberculosis and HIV infection Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Convalescent Plasma does not improve in-hospital mortality among low SARS-CoV-2-IgG antibodies in COVID-19 hospitalized patients Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021
Changes in plasma pyridoxal levels during standard treatment tuberculosis Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014
Serum acute phase reactants in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 312s Year: 2002
Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
CVA: serum ECP in the management of steroid therapy Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005
Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections Year: 2013
Blood and urine IP-10 associate with active TB in HIV-infected patients Source: International Congress 2016 – Latent tuberculosis infection Year: 2016
Oral human serum immunoglobulin for norovirus diarrhea in pulmonary transplant patients Source: Annual Congress 2013 –Clinical studies in lung transplantation Year: 2013
Relation of plasma osteopontin levels with the clinical course in patients with COPD Source: International Congress 2014 – Systemic and airway biomarkers Year: 2014
Plasma concentration of isoniazid and rifampin in new tuberculosis patients with and without diabetes mellitus Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Serum YKL-40 is elevated in children with pneumonia and RSV infection Source: International Congress 2014 – Virus-triggered lower respiratory disease in children Year: 2014
Serum lipids as biomarkers for therapeutic monitoring of latent tuberculosis infection Source: Eur Respir J 2013; 42: 547-550 Year: 2013
Analysis of serum cytokine levels before and after isoprinosine treatment in children with acute viral respiratory infections Source: Annual Congress 2010 - From viral bronchiolitis to recurrent pneumonia in childhood: diagnosis, treatment and underlying factors Year: 2010